Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BEAMNASDAQ:GMTXNASDAQ:RLAYNASDAQ:TARS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBEAMBeam Therapeutics$19.52-3.2%$22.18$13.53▼$35.25$1.96B2.021.39 million shs1.22 million shsGMTXGemini Therapeutics$45.42-1.6%$48.74$1.16▼$14.10$1.97B-0.12189,291 shs273,679 shsRLAYRelay Therapeutics$3.20+0.3%$3.02$1.78▼$10.72$542.47M1.71.99 million shs1.64 million shsTARSTarsus Pharmaceuticals$50.00+0.1%$47.60$20.08▼$57.28$1.92B0.94689,977 shs754,503 shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBEAMBeam Therapeutics0.00%+14.82%-12.03%-24.87%-14.16%GMTXGemini Therapeutics-1.62%+7.72%-13.47%-20.94%+68.22%RLAYRelay Therapeutics0.00%+18.96%+7.02%-34.02%-49.61%TARSTarsus Pharmaceuticals0.00%+1.52%-1.28%+2.50%+52.63%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBEAMBeam Therapeutics3.0156 of 5 stars4.51.00.00.02.42.50.6GMTXGemini TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ARLAYRelay Therapeutics2.0311 of 5 stars3.41.00.00.02.12.50.6TARSTarsus Pharmaceuticals2.2068 of 5 stars3.50.00.00.03.52.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBEAMBeam Therapeutics 3.00Buy$49.45153.35% UpsideGMTXGemini Therapeutics 0.00N/AN/AN/ARLAYRelay Therapeutics 2.82Moderate Buy$18.36473.86% UpsideTARSTarsus Pharmaceuticals 3.00Buy$63.6727.33% UpsideCurrent Analyst Ratings BreakdownLatest RLAY, TARS, GMTX, and BEAM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/17/2025RLAYRelay TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageEqual Weight$4.004/7/2025BEAMBeam TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.00 ➝ $80.003/28/2025BEAMBeam TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$42.00 ➝ $42.003/12/2025BEAMBeam TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight3/10/2025BEAMBeam TherapeuticsJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$34.003/10/2025BEAMBeam TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.00 ➝ $80.003/10/2025BEAMBeam TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$57.003/10/2025BEAMBeam TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeSector Perform ➝ Sector Outperform$40.003/7/2025RLAYRelay TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.003/6/2025TARSTarsus PharmaceuticalsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$54.00 ➝ $58.003/3/2025BEAMBeam TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Perform ➝ Sector Perform$24.00 ➝ $25.00(Data available from 4/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBEAMBeam Therapeutics$63.52M30.90N/AN/A$12.04 per share1.62GMTXGemini TherapeuticsN/AN/AN/AN/A$2.89 per shareN/ARLAYRelay Therapeutics$10.01M54.21N/AN/A$5.90 per share0.54TARSTarsus Pharmaceuticals$182.95M10.49N/AN/A$5.95 per share8.40Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBEAMBeam Therapeutics-$132.53M-$4.58N/AN/AN/A-41.07%-16.22%-10.94%5/6/2025 (Estimated)GMTXGemini Therapeutics-$71.87M-$1.00N/AN/AN/AN/A-38.78%-35.88%N/ARLAYRelay Therapeutics-$341.97M-$2.39N/AN/AN/AN/A-45.75%-40.75%5/1/2025 (Estimated)TARSTarsus Pharmaceuticals-$135.89M-$3.10N/AN/AN/A-103.64%-55.86%-39.28%5/6/2025 (Estimated)Latest RLAY, TARS, GMTX, and BEAM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025TARSTarsus Pharmaceuticals-$0.75N/AN/AN/A$71.19 millionN/A5/6/2025Q1 2025BEAMBeam Therapeutics-$1.11N/AN/AN/A$14.69 millionN/A5/1/2025Q1 2025RLAYRelay Therapeutics-$0.51N/AN/AN/A$0.01 millionN/A2/26/2025Q4 2024RLAYRelay Therapeutics-$0.57-$0.45+$0.12-$0.45$5.53 millionN/A2/25/2025Q4 2024BEAMBeam Therapeutics-$1.25-$1.09+$0.16-$1.09$16.47 million$30.00 million2/25/2025Q4 2024TARSTarsus Pharmaceuticals-$0.68-$0.60+$0.08-$0.60$58.80 million$66.41 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBEAMBeam Therapeutics$0.904.61%N/AN/A N/AGMTXGemini TherapeuticsN/AN/AN/AN/AN/ARLAYRelay TherapeuticsN/AN/AN/AN/AN/ATARSTarsus PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBEAMBeam TherapeuticsN/A5.695.69GMTXGemini TherapeuticsN/A71.4971.49RLAYRelay TherapeuticsN/A18.4218.42TARSTarsus Pharmaceuticals0.305.425.38Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBEAMBeam Therapeutics99.68%GMTXGemini Therapeutics75.42%RLAYRelay Therapeutics96.98%TARSTarsus Pharmaceuticals90.01%Insider OwnershipCompanyInsider OwnershipBEAMBeam Therapeutics4.20%GMTXGemini Therapeutics12.90%RLAYRelay Therapeutics4.32%TARSTarsus Pharmaceuticals8.25%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBEAMBeam Therapeutics510100.56 million79.33 millionOptionableGMTXGemini Therapeutics3043.33 million37.74 millionNot OptionableRLAYRelay Therapeutics330169.52 million160.15 millionOptionableTARSTarsus Pharmaceuticals5038.38 million35.07 millionOptionableRLAY, TARS, GMTX, and BEAM HeadlinesRecent News About These CompaniesTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Acquired by Wells Fargo & Company MNApril 26 at 3:18 AM | marketbeat.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Bought by Canada Pension Plan Investment BoardApril 25 at 4:22 AM | marketbeat.comTarsus Pharmaceuticals to Host Live Webcast for Q1 2025 Financial Results and Corporate UpdateApril 24 at 5:13 PM | quiverquant.comTarsus to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025April 24 at 5:00 PM | globenewswire.comSilverarc Capital Management LLC Grows Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)April 24 at 7:36 AM | marketbeat.comDiadema Partners LP Makes New $3.32 Million Investment in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)April 24 at 7:16 AM | marketbeat.comTarsus Pharmaceuticals to present abstracts on XDEMVY at ASCRS meetingApril 24 at 5:38 AM | markets.businessinsider.comRock Springs Capital Management LP Invests $6.14 Million in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)April 23, 2025 | marketbeat.comTarsus to Present Several Scientific Abstracts Highlighting the Global Prevalence of Demodex Blepharitis and the Clinical Impact of XDEMVY at the American Society of Cataract and Refractive Surgery (ASCRS) 2025 Annual MeetingApril 22, 2025 | globenewswire.comOC Drugmakers Grow Workforce 7%April 21, 2025 | ocbj.comAlpha DNA Investment Management LLC Purchases New Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)April 21, 2025 | marketbeat.comXTX Topco Ltd Takes Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)April 21, 2025 | marketbeat.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Sold by JPMorgan Chase & Co.April 19, 2025 | marketbeat.comEAM Investors LLC Makes New Investment in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)April 18, 2025 | marketbeat.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Position Raised by Invesco Ltd.April 18, 2025 | marketbeat.com77,714 Shares in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Acquired by Federated Hermes Inc.April 15, 2025 | marketbeat.comAdvisory Services Network LLC Purchases 22,648 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)April 13, 2025 | marketbeat.comWellington Management Group LLP Has $7.57 Million Stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)April 13, 2025 | marketbeat.comTarsus Pharmaceuticals (NASDAQ:TARS) Trading Down 7.2% - Should You Sell?April 11, 2025 | marketbeat.comCapula Management Ltd Makes New Investment in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)April 10, 2025 | marketbeat.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Bought by Vanguard Group Inc.April 10, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRLAY, TARS, GMTX, and BEAM Company DescriptionsBeam Therapeutics NASDAQ:BEAM$19.52 -0.65 (-3.22%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$20.00 +0.48 (+2.43%) As of 04/25/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.Gemini Therapeutics NASDAQ:GMTX$45.42 -0.75 (-1.62%) As of 04/25/2025Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.Relay Therapeutics NASDAQ:RLAY$3.20 +0.01 (+0.31%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$3.16 -0.04 (-1.25%) As of 04/25/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Tarsus Pharmaceuticals NASDAQ:TARS$50.00 +0.03 (+0.06%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$49.94 -0.06 (-0.12%) As of 04/25/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 04/21 - 04/25 Bears Can Reap Big Benefits With These 3 Short ETF Bets If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy 3 Stocks To Watch For When Tariffs Subside 3 Boring Stocks Outperforming the Market This Year Short Sellers Gave Up on These 3 Names Recently Churchill Downs Stock: Could Tariff Fears Dampen Derby Gains? Markets Think Robinhood Earnings Could Send the Stock Up Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
